OC
MCRB icon

Oppenheimer & Co’s Seres Therapeutics MCRB Stock Holding History

Oppenheimer & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,079
Closed -$99K – 1426
2023
Q3 		$99K Buy
2,079
+138
+7% +$10.5K ﹤0.01% 1322
2023
Q2 		$186K Buy
1,941
+85
+5% +$9.25K ﹤0.01% 1296
2023
Q1 		$210K Buy
+1,856
New +$201K ﹤0.01% 1249

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's MCRB Position: Q4 2023 in Review

Oppenheimer & Co sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 2,079 shares — an estimated $99K sold.

Oppenheimer & Co first reported a position in MCRB in Q1 2023 and held it in 3 quarters. The position peaked at $210K in Q1 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Oppenheimer & Co reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 2,079 Seres Therapeutics shares in Q4 2023, an estimated $99K.
  • Oppenheimer & Co first reported a position in Seres Therapeutics in Q1 2023 and held it in 3 quarters.
  • Oppenheimer & Co's Seres Therapeutics position peaked at $210K in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Oppenheimer & Co's 13F filing for Q4 2023, filed 13 Feb 2024.